Article
TP53 mutations in older adults with acute myeloid leukemia.
International journal of hematology - 1 Apr 2016
Yanada Masamitsu, Yamamoto Yukiya, Iba Sachiko, Okamoto Akinao, Inaguma Yoko, Tokuda Masutaka, Morishima Satoko, Kanie Tadaharu, Mizuta Shuichi, Akatsuka Yoshiki, Okamoto Masataka, Emi Nobuhiko
Abstract excerpt
The net benefits of induction therapy for older adults with acute myeloid leukemia (AML) remain controversial. Because AML in older adults is a heterogeneous disease, it is important to identify those who are unlikely to benefit from induction therapy based on information available at the initial assessment. We used next-generation sequencing to analyze TP53 mutation status in AML patients aged 60 years or older,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.